In the post-COVID-19 path to recovery, pharmaceutical leaders have increased their focus on risk management, transparent operations, and reshaping the future of their workforces.

Given the shifts that have taken place seemingly overnight, companies are forced to conceptualize the “new normal” at a rapid pace, considering internal challenges, industry impact, and the relationship in a multi-payer market, including government involvement.

This is without even mentioning the added complexity caused by the ramifications of the 2020 Presidential Election outcome in US.

It’s no easy task. To successfully commercialize in the US, organizations must scope next steps from 3 main optics:

  • The Pharma/Biotech perspective
  • The considerations for the industry
  • The implications for governments

Only then will commercial strategies be robust, yet agile and ready to with stand political, healthcare, regulatory and market changes.

Join this c-suite leadership briefing (in webinar format) to gain vital insights, from pharma and healthcare leaders, into how your commercial strategy needs to adapt.

Panelists include:

Kathleen Sebelius

Kathleen Sebelius Former United States Secretary of Health and Human Services and CEO Sebelius Resources LLC

Joe Jimenez

Joe Jimenez Ex-Novartis CEO, and CEO & Co-Founder Aditum Bio

Kabir Nath

Kabir Nath Senior Managing Director, Global Pharmaceutical Business Otsuka Pharmaceutical Co., Ltd

Jim Lang




Paul Simms Pharma Provocateur